LZ
LZAGY.US Lonza Group AG
- Market cap
- USD 56.4B
- P/E
- 41.7x
- P/B
- 5.67x
- ROE
- 29.7%
- Dividend yield
- 0.80%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is LZAGY.US undervalued?
Graham numberThe Graham number of Lonza Group AG cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lonza Group AG fundamental analysis
No fundamental analysis for Lonza Group AG yet.
Lonza Group AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manuf…
Full company profileLonza Group AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lonza Group AG annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.13B | 4.55B | 5.54B | 4.21B | 4.51B | 5.41B | 6.22B | 6.72B | 6.57B | 6.53B | 13.8B |
| Gross Profit | 1.46B | 1.78B | 2.18B | 1.78B | 1.71B | 2.11B | 2.44B | 1.95B | 2.16B | 2.31B | 5.29B |
| Operating Income | 617M | 821M | 1.01B | 918M | 901M | 851M | 1.54B | 880M | 964M | 1.32B | 3.29B |
| EBITDA | 755M | 1.02B | 1.43B | 1.34B | 1.47B | 1.37B | 1.98B | 1.53B | 1.54B | 1.88B | 4.67B |
| Net Income | 301M | 726M | 559M | 645M | 869M | 2.94B | 1.22B | 654M | 636M | 949M | 2.41B |
| EPS | 0.57 | 1.06 | 0.75 | 0.87 | 1.16 | 3.95 | 1.63 | 0.89 | 0.89 | 1.35 | 3.45 |
| Balance Sheet | |||||||||||
| Total Assets | 6.83B | 13.8B | 13.9B | 13.8B | 14.6B | 16.5B | 17.4B | 16.8B | 19.7B | 19.0B | 18.3B |
| Total Liabilities | 4.47B | 7.65B | 7.63B | 7.28B | 7.74B | 6.64B | 6.69B | 7.34B | 10.3B | 9.78B | 10.1B |
| Shareholders' Equity | 2.36B | 6.13B | 6.22B | 6.49B | 6.82B | 9.75B | 10.6B | 9.45B | 9.33B | 9.13B | 8.12B |
| Cash & Short-term Investments | 286M | 487M | 462M | 505M | 495M | 3.18B | 2.22B | 1.67B | 1.71B | 719M | 487M |
| Total Debt | 1.86B | 4.25B | 4.06B | 3.78B | 3.81B | 2.75B | 2.59B | 3.13B | 5.12B | 4.54B | 4.17B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 752M | 841M | 1.08B | 986M | 1.13B | 1.22B | 1.02B | 1.39B | 1.27B | 1.12B | 2.70B |
| Capital Expenditure | 355M | 420M | 528M | 807M | 973M | 1.34B | 1.87B | 1.65B | 1.42B | 1.31B | 2.37B |
| Free Cash Flow | 397M | 421M | 554M | 179M | 157M | -124M | -852M | -263M | -143M | -195M | 331M |
| Ratios | |||||||||||
| ROE | 12.8% | 11.8% | 9.0% | 9.9% | 12.8% | 30.2% | 11.5% | 6.9% | 6.8% | 10.4% | 29.7% |
| ROA | 4.4% | 5.2% | 4.0% | 4.7% | 5.9% | 17.9% | 7.0% | 3.9% | 3.2% | 5.0% | 13.2% |
| Net Profit Margin | 7.3% | 16.0% | 10.1% | 15.3% | 19.3% | 54.4% | 19.5% | 9.7% | 9.7% | 14.5% | 17.5% |
| Debt to Equity | 0.79x | 0.69x | 0.65x | 0.58x | 0.56x | 0.28x | 0.24x | 0.33x | 0.55x | 0.50x | 0.51x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lonza Group AG dividends
- Dividend yield
- 0.80%
- Forward dividend
- 0.63 USD
- Payout ratio
- 28.2%
- Ex-dividend date
- May 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CHF 267M | 0.38 | 28.2% |
| 2024 | CHF 288M | 0.40 | 45.3% |
| 2023 | CHF 260M | 0.35 | 39.8% |
| 2022 | CHF 228M | 0.31 | 18.8% |
| 2021 | CHF 225M | 0.30 | 7.6% |
| 2020 | CHF 206M | 0.28 | 23.7% |
| 2019 | CHF 206M | 0.28 | 31.9% |
| 2018 | CHF 206M | 0.28 | 36.9% |
| 2017 | CHF 160M | 0.23 | 22.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1079:1000 on May 2, 2017.
Who owns Lonza Group AG
- Insiders 0.00%
- Institutions 0.04%
- Public & others 99.96%
- Shares outstanding 698M
- Free float 697M
Lonza Group AG company profile
- Company name
- Lonza Group AG
- Ticker
- LZAGY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20,141
- Fiscal year end
- December
- Address
- Muenchensteinerstrasse 38, Basel, Switzerland, 4002
- Phone
- 41 61 316 81 11
- Website
- lonza.com
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Lonza Group AG management
10- Dr. Wolfgang Wienand Ph.D.Chief Executive Officer · born 1972
- Mr. Philippe DeeckeChief Financial Officer
- Mr. Jason BerndtExecutive VP & Head of Group Operations
- Mr. Daniel BuchtaHead of Investor Relations
- Mr. Andreas BohrerChief Legal & Corporate Affairs Officer
- Ms. Kim HarrelsonHead of Ethics & Compliance, ERM and Corporate Responsibility
- Mr. Hans TreesSenior VP & Global Head of Communications
- Ms. Jennifer ClancySenior Director of Global Marketing
- Ms. Nicoleta BaumgartnerChief Human Resources Officer · born 1971
- Dr. Matthias HofmannHead of Corporate Environment, Health, Safety & Global Sustainability